Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 3
Submit an article Journal homepage
130
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Blast clearance after one week of corticosteroids correlates with outcome and genetics but does not justify adding a residual disease time point in acute lymphoblastic leukemia treatment

Barbora Vakrmanovaa Department of Paediatric Haematology and Oncology, Charles University, Second Faculty of Medicine, CLIP, Prague, Czech RepublicView further author information
,
Eva Fronkovaa Department of Paediatric Haematology and Oncology, Charles University, Second Faculty of Medicine, CLIP, Prague, Czech Republic;b Department of Paediatric Haematology and Oncology, Motol University Hospital, Prague, Czech RepublicView further author information
,
Jan Zunaa Department of Paediatric Haematology and Oncology, Charles University, Second Faculty of Medicine, CLIP, Prague, Czech Republic;b Department of Paediatric Haematology and Oncology, Motol University Hospital, Prague, Czech RepublicView further author information
,
Iveta Janotovab Department of Paediatric Haematology and Oncology, Motol University Hospital, Prague, Czech RepublicView further author information
,
Yahia Jabalic Hospital Ceske Budejovice, Czech RepublicView further author information
,
Leona Rezkova Reznickovaa Department of Paediatric Haematology and Oncology, Charles University, Second Faculty of Medicine, CLIP, Prague, Czech RepublicView further author information
,
Katerina Zdrahalovab Department of Paediatric Haematology and Oncology, Motol University Hospital, Prague, Czech RepublicView further author information
,
Jan Trkaa Department of Paediatric Haematology and Oncology, Charles University, Second Faculty of Medicine, CLIP, Prague, Czech Republic;b Department of Paediatric Haematology and Oncology, Motol University Hospital, Prague, Czech RepublicView further author information
,
Jan Staryb Department of Paediatric Haematology and Oncology, Motol University Hospital, Prague, Czech RepublicView further author information
,
Ondrej Hrusaka Department of Paediatric Haematology and Oncology, Charles University, Second Faculty of Medicine, CLIP, Prague, Czech Republic;b Department of Paediatric Haematology and Oncology, Motol University Hospital, Prague, Czech RepublicView further author information
&
Ester Mejstrikovaa Department of Paediatric Haematology and Oncology, Charles University, Second Faculty of Medicine, CLIP, Prague, Czech Republic;b Department of Paediatric Haematology and Oncology, Motol University Hospital, Prague, Czech RepublicCorrespondence[email protected]
View further author information
 show all
Pages 752-754 | Received 30 Jun 2020, Accepted 13 Oct 2020, Published online: 29 Oct 2020

References

  • Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on Day 15 bone marrow. J Cin Oncol. 2009;27(31):5168–5174.
  • Riehm H, Reiter A, Schrappe M, et al. Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83) TT – the in vivo response on corticosteroid therapy as an additional prognostic factor in childhood acute lymphoblastic leukemia (therapy study ALL-BFM 83). Klin Padiatr. 1987;199(3):151–160.
  • Volejnikova J, Mejstrikova E, Valova T, et al. Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis. Haematologica. 2011;96(12):1815–1821.
  • Borowitz MJ, Pullen DJ, Shuster JJ, et al. Minimal residual disease detection in childhood precursor – B-cell acute lymphoblastic leukemia: relation to other risk factors. A children’s oncology group study. Leukemia. 2003;17:1566–1572.
  • Stary J, Zimmermann M, Campbell M, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol. 2014;32(3):174–184.
  • Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 2012;13(9):936–945.
  • Mejstříková E, Froňková E, Kalina T, et al. Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry. Pediatr Blood Cancer. 2010;54(1):62–70.
  • Fronkova E, Mejstrikova E, Avigad S, et al. Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia 2008;22:989–997.
  • Schumich A, Maurer-Granofszky M, Attarbaschi A, et al. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000. Pediatr Blood Cancer. 2019;66:e27590.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.